Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dynavax Technologies Corporation
The purpose of the study is to evaluate the safety, immunogenicity and lot-to-lot consistency of an investigational hepatitis B virus vaccine, HEPLISAV™, in healthy adults 40 to 70 years of age
Age
40–70
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
be 40 - 70 years of age, inclusive
be seronegative for hepatitis B surface antigen (HBsAg), antibody against hepatitis B surface antigen (anti-HBsAg), antibody against hepatitis B core antigen (anti-HBcAg), and human immunodeficiency virus (HIV)
be in good health in the opinion of the investigator, based upon medical history, physical examination, and laboratory evaluation
if female of childbearing potential, agree to consistently use a highly effective method of birth control from screening visit through the treatment phase, for up to 28 days after the last injection
You may not be if
if female of childbearing potential, is pregnant, breastfeeding, or planning a pregnancy
has a history of or is considered by the investigator to be at high risk for recent exposure to HBV or HIV; for example, current intravenous drug use or has unprotected sex with known HBV/HIV positive partner
has a known history of autoimmune disease
has previously received any hepatitis B vaccine (approved or investigational)
Clareo Health | Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine
